PR Newswire
– Company Also Announces Participation in the BTIG Biotechnology Conference and the Stifel Biotech Summer Summit –
SEATTLE , Aug. 1, 2022 /PRNewswire/ -- CTI BioPharma Corp. ( CTI BioPharma ) ( NASDAQ : CTIC ) today announced that management plans to report its second quarter 2022 financial results on Monday, August 8, 2022 , after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p . m . ET (1:30 p . m . PT).
To access the live call by phone please dial (888) 317-6003 (domestic) or (412) 317-6061 (international); the conference ID is 0078819. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com . A replay of the webcast will be available for 30 days following the event.
August Conferences
CTI BioPharma also announced that it will participate in one-on-one meetings at the BTIG Biotechnology Conference on August 9, 2022 . Additionally, the Company will participate in a fireside chat and one-on-one meetings at the Stifel Biotech Summer Summit on Tuesday, August 16, 2022 , at 11:00 am E.T.
The Stifel fireside chat will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com .
About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO ® (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10 9 /L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO ® is a registered trademark of CTI BioPharma Corp.
CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com
SOURCE CTI BioPharma Corp.